PRRT2 and neoplasm: Downregulation of MiR-205 has been observed in a panel of cancers, such as breast, prostate, bladder and gliomas and head and neck, pointing to a tumor-suppressor activity of MiR-205.14, 34, 35, 36, 37, 38 Indeed, most of its targets identified so far are oncogenes (e.g., ErbB3, VEGF-A, ZEB1/2, ZEB1/2, ΔNp63α, SFK and PKCɛ).18 Simultaneously, however, evidence for an oncogenic role of MiR-205 also began to accumulate.